Logo image of MXCT

MAXCYTE INC (MXCT) Stock Price, Quote, News and Overview

NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD

2.3417  -0.09 (-3.63%)

MXCT Quote, Performance and Key Statistics

MAXCYTE INC

NASDAQ:MXCT (5/9/2025, 10:15:07 AM)

2.3417

-0.09 (-3.63%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High5.26
52 Week Low2.21
Market Cap248.95M
Shares106.31M
Float99.48M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO03-29 2016-03-29


MXCT short term performance overview.The bars show the price performance of MXCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

MXCT long term performance overview.The bars show the price performance of MXCT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of MXCT is 2.3417 USD. In the past month the price decreased by -3.95%. In the past year, price decreased by -48.73%.

MAXCYTE INC / MXCT Daily stock chart

MXCT Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 18.63 154.03B
DHR DANAHER CORP 25.91 138.12B
A AGILENT TECHNOLOGIES INC 20.25 30.66B
IQV IQVIA HOLDINGS INC 13.55 26.99B
MTD METTLER-TOLEDO INTERNATIONAL 27.21 22.94B
WAT WATERS CORP 29.26 20.73B
WST WEST PHARMACEUTICAL SERVICES 32.22 15.37B
ILMN ILLUMINA INC 22.77 12.00B
ICLR ICON PLC 10.06 11.40B
RVTY REVVITY INC 18.67 11.06B
TEM TEMPUS AI INC N/A 11.02B
QGEN QIAGEN N.V. 18.54 9.22B

About MXCT

Company Profile

MXCT logo image MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Company Info

MAXCYTE INC

9713 Key West Avenue,, Suite 400

Rockville MARYLAND US

CEO: Doug Doerfler

Employees: 114

MXCT Company Website

MXCT Investor Relations

Phone: 13015175556

MAXCYTE INC / MXCT FAQ

What is the stock price of MAXCYTE INC today?

The current stock price of MXCT is 2.3417 USD. The price decreased by -3.63% in the last trading session.


What is the ticker symbol for MAXCYTE INC stock?

The exchange symbol of MAXCYTE INC is MXCT and it is listed on the Nasdaq exchange.


On which exchange is MXCT stock listed?

MXCT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MAXCYTE INC stock?

11 analysts have analysed MXCT and the average price target is 7.48 USD. This implies a price increase of 219.42% is expected in the next year compared to the current price of 2.3417. Check the MAXCYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MAXCYTE INC worth?

MAXCYTE INC (MXCT) has a market capitalization of 248.95M USD. This makes MXCT a Micro Cap stock.


How many employees does MAXCYTE INC have?

MAXCYTE INC (MXCT) currently has 114 employees.


What are the support and resistance levels for MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a resistance level at 4.81. Check the full technical report for a detailed analysis of MXCT support and resistance levels.


Is MAXCYTE INC (MXCT) expected to grow?

The Revenue of MAXCYTE INC (MXCT) is expected to grow by 9.03% in the next year. Check the estimates tab for more information on the MXCT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MAXCYTE INC (MXCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MAXCYTE INC (MXCT) stock pay dividends?

MXCT does not pay a dividend.


What is the Price/Earnings (PE) ratio of MAXCYTE INC (MXCT)?

MAXCYTE INC (MXCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).


What is the Short Interest ratio of MAXCYTE INC (MXCT) stock?

The outstanding short interest for MAXCYTE INC (MXCT) is 3.5% of its float. Check the ownership tab for more information on the MXCT short interest.


MXCT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MXCT Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to MXCT. MXCT has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MXCT Financial Highlights

Over the last trailing twelve months MXCT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -14.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.14%
ROE -19.91%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-11.11%
Sales Q2Q%-8.39%
EPS 1Y (TTM)-14.29%
Revenue 1Y (TTM)-6.44%

MXCT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to MXCT. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 6.89% and a revenue growth 9.03% for MXCT


Ownership
Inst Owners69.8%
Ins Owners0.82%
Short Float %3.5%
Short Ratio5.09
Analysts
Analysts87.27
Price Target7.48 (219.43%)
EPS Next Y6.89%
Revenue Next Year9.03%